Kenvue /$KVUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kenvue
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
Ticker
$KVUE
Sector
Primary listing
NYSE
Industry
Personal Care Products
Headquarters
Employees
22,000
ISIN
US49177J1025
Website
Kenvue Metrics
BasicAdvanced
$41B
38.73
$0.55
0.97
$0.82
3.84%
Price and volume
Market cap
$41B
Beta
0.97
52-week high
$25.17
52-week low
$17.67
Average daily volume
20M
Dividend rate
$0.82
Financial strength
Current ratio
0.857
Quick ratio
0.505
Long term debt to equity
63.513
Total debt to equity
88.043
Dividend payout ratio (TTM)
147.82%
Interest coverage (TTM)
6.76%
Profitability
EBITDA (TTM)
3,509
Gross margin (TTM)
58.09%
Net profit margin (TTM)
6.90%
Operating margin (TTM)
18.95%
Effective tax rate (TTM)
26.97%
Revenue per employee (TTM)
$700,000
Management effectiveness
Return on assets (TTM)
6.77%
Return on equity (TTM)
10.22%
Valuation
Price to earnings (TTM)
38.73
Price to revenue (TTM)
2.673
Price to book
4.08
Price to tangible book (TTM)
-5.34
Price to free cash flow (TTM)
28.323
Free cash flow yield (TTM)
3.53%
Free cash flow per share (TTM)
75.41%
Dividend yield (TTM)
3.84%
Forward dividend yield
3.84%
Growth
Revenue change (TTM)
-1.19%
Earnings per share change (TTM)
-29.62%
What the Analysts think about Kenvue
Analyst ratings (Buy, Hold, Sell) for Kenvue stock.
Bulls say / Bears say
Kenvue's first-quarter 2025 results exceeded expectations, with adjusted earnings of $0.24 per share and revenue of $3.74 billion, driven by strong demand for self-care products like Tylenol and Benadryl. (reuters.com)
Activist investor Starboard Value has taken a significant stake in Kenvue, indicating potential for strategic changes to enhance shareholder value. (reuters.com)
Analysts have a consensus 'Buy' rating for Kenvue, with a 12-month price target of $23.75, suggesting potential upside from current levels. (stockanalysis.com)
Kenvue's skin health and beauty segment, including brands like Neutrogena and Aveeno, reported a 7.3% decline in sales to $977 million in Q1 2025, underperforming analyst expectations. (reuters.com)
The company forecasts flat annual profit for 2025, citing rising costs from U.S. import tariffs, which could pressure margins. (reuters.com)
Kenvue's stock has declined approximately 13.2% since its IPO in May 2022, reflecting investor concerns over growth prospects and competitive pressures. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 29 May 2025.
Kenvue Financial Performance
Revenues and expenses
Kenvue Earnings Performance
Company profitability
Kenvue News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kenvue stock?
Kenvue (KVUE) has a market cap of $41B as of June 20, 2025.
What is the P/E ratio for Kenvue stock?
The price to earnings (P/E) ratio for Kenvue (KVUE) stock is 38.73 as of June 20, 2025.
Does Kenvue stock pay dividends?
Yes, the Kenvue (KVUE) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $0.82 and the yield is 3.84%. Kenvue has a payout ratio of 147.82% on a trailing twelve-month basis.
When is the next Kenvue dividend payment date?
The next Kenvue (KVUE) dividend payment date is unconfirmed.
What is the beta indicator for Kenvue ?
Kenvue (KVUE) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.